Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and Weekly Paclitaxel and Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Carcinoma: A Real-World Study.

Conclusions: HER2+ BC patients showed improvement in pCR and DFS after neoadjuvant trastuzumab treatment. Patients without pCR had prolonged DFS after trastuzumab maintenance. Although the prognosis of luminal B/HER2+ BC showed favorable outcomes in the non-pCR subgroup, those receiving trastuzumab showed no survival advantage.
PMID: 32461977 [PubMed - in process]

Source: Biomed Res - May 30, 2020 Category: Research Authors: Zhang M, Li L, Zhang S, Zhu W, Yang S, Di G, Ma X, Yang H Tags: Biomed Res Int Source Type: research